Adamas Pharmaceuticals Shares Outstanding 2013-2018 | ADMS

Adamas Pharmaceuticals shares outstanding history from 2013 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Adamas Pharmaceuticals shares outstanding for the quarter ending June 30, 2018 were 0.027B, a 20.76% increase year-over-year.
  • Adamas Pharmaceuticals 2017 shares outstanding were 0.023B, a 3.9% increase from 2016.
  • Adamas Pharmaceuticals 2016 shares outstanding were 0.022B, a 19.88% increase from 2015.
  • Adamas Pharmaceuticals 2015 shares outstanding were 0.018B, a 5.87% increase from 2014.
Adamas Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2017 23
2016 22
2015 18
2014 17
2013 12
2012 10
Adamas Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 27
Q1 2018 26
Q4 2017 23
Q3 2017 23
Q2 2017 22
Q1 2017 22
Q4 2016 22
Q3 2016 22
Q2 2016 22
Q1 2016 21
Q4 2015 18
Q3 2015 18
Q2 2015 18
Q1 2015 18
Q4 2014 17
Q3 2014 17
Q2 2014 19
Q1 2014 10
Q4 2013 12
Q3 2013 10
Q2 2013 10
Q1 2013 11
Q4 2012 0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.485B $0.001B
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $64.335B 11.04
Teva Pharmaceutical Industries (TEVA) Israel $21.792B 6.09
Mylan (MYL) United Kingdom $16.606B 7.06
Bausch Health Cos (BHC) Canada $8.483B 6.32
Dr Reddy's Laboratories (RDY) India $5.756B 25.71
Supernus Pharmaceuticals (SUPN) United States $2.517B 26.93
Mallinckrodt Public (MNK) United Kingdom $2.287B 3.89
Akorn (AKRX) United States $0.882B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.857B 123.53
Homology Medicines (FIXX) United States $0.747B 0.00
CymaBay Therapeutics (CBAY) United States $0.615B 0.00
Assembly Biosciences (ASMB) United States $0.594B 0.00
Voyager Therapeutics (VYGR) United States $0.498B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.482B 0.00
Corium (CORI) United States $0.454B 0.00
Teligent (TLGT) United States $0.185B 0.00
Sol-Gel Technologies (SLGL) Israel $0.125B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.120B 0.00
Aevi Genomic Medicine (GNMX) United States $0.074B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.061B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Agile Therapeutics (AGRX) United States $0.033B 0.00
China Pharma Holdings (CPHI) China $0.019B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00